Can-Fite BioPharma Ltd. (IL:CANF)
TASE:CANF
Want to see IL:CANF full AI Analyst Report?
CANF Stock Chart & Stats
732.30
>-0.01(-4.76%)
At close: 4:00 PM EST
732.30
>-0.01(-4.76%)
Day’s Range― - ―
52-Week Range422.00 - 4,200.00
Previous CloseN/A
Volume13.23M
Average Volume (3M)1.04M
Market Cap
₪19.14M
Enterprise Value7.56B
Total Cash (Recent Filing)₪6.46M
Total Debt (Recent Filing)₪90.00K
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Aug 27, 2026EPS Estimate
-75.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding4,285,093
10 Day Avg. Volume130,742
30 Day Avg. Volume1,039,800
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.77
Price to Sales (P/S)35.39
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength (low Leverage)Minimal debt and low leverage materially reduce near-term financial risk for a clinical-stage biotech. This structural strength provides flexibility to fund trials, negotiate partnerships, or tolerate development delays without immediate solvency pressure, supporting multi‑quarter resilience.
High Gross Margin PotentialExtremely high gross margins reflect the underlying economics of small‑molecule drug sales and clinical assets if commercialized. Structurally, high product margins can translate into strong cash generation post-approval and make partnering or licensing economics attractive to larger pharma.
Focused Clinical-stage Pipeline And MechanismA concentrated pipeline targeting the A3 adenosine receptor with two lead candidates concentrates R&D expertise and capital, increasing chance of clear development milestones. This focused strategy can produce discrete value inflection points and facilitate targeted partnerships or licensing.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the company is not self-funding its development. Over multiple quarters this structural cash burn necessitates external financing, increasing dilution risk and potentially constraining continuous trial progress or strategic optionality.
Shrinking Revenue And Large Operating LossesA multi‑year decline in minimal revenue coupled with widening operating losses indicates the business is not scaling and is structurally loss-making. This undermines prospects for near‑term self-sufficiency and raises risk that continued R&D investment cannot be sustained without capital raises.
Very Small Team / Limited Internal ScaleAn extremely small headcount constrains internal capacity to run multiple clinical programs, manage regulatory interactions, or prepare commercialization. Long-term execution will rely heavily on outsourcing and external partners, increasing operational risk and governance complexity.
Can Fite Bio News
CANF FAQ
What was Can-Fite BioPharma Ltd.’s price range in the past 12 months?
Can-Fite BioPharma Ltd. lowest stock price was 422.00 and its highest was 4200.00 in the past 12 months.
What is Can-Fite BioPharma Ltd.’s market cap?
Can-Fite BioPharma Ltd.’s market cap is ₪19.14M.
When is Can-Fite BioPharma Ltd.’s upcoming earnings report date?
Can-Fite BioPharma Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 65 days.
How were Can-Fite BioPharma Ltd.’s earnings last quarter?
Can-Fite BioPharma Ltd. released its earnings results on Mar 26, 2026. The company reported -884.667 earnings per share for the quarter, missing the consensus estimate of -20.746 by -863.921.
Is Can-Fite BioPharma Ltd. overvalued?
According to Wall Street analysts Can-Fite BioPharma Ltd.’s price is currently Overvalued.
Does Can-Fite BioPharma Ltd. pay dividends?
Can-Fite BioPharma Ltd. does not currently pay dividends.
What is Can-Fite BioPharma Ltd.’s EPS estimate?
Can-Fite BioPharma Ltd.’s EPS estimate is -75.28.
How many shares outstanding does Can-Fite BioPharma Ltd. have?
Can-Fite BioPharma Ltd. has 4,285,093 shares outstanding.
What happened to Can-Fite BioPharma Ltd.’s price movement after its last earnings report?
Can-Fite BioPharma Ltd. reported an EPS of -884.667 in its last earnings report, missing expectations of -20.746. Following the earnings report the stock price went down -0.719%.
Which hedge fund is a major shareholder of Can-Fite BioPharma Ltd.?
Currently, no hedge funds are holding shares in IL:CANF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. is an Israel-based, clinical-stage biopharmaceutical firm dedicated to developing small molecule therapeutic agents. Its research and development efforts are concentrated on addressing conditions such as cancer, various liver inflammatory diseases, and erectile dysfunction. The company's lead investigational compound, Piclidenoson, has progressed through successful completion of its Phase III clinical trial for psoriasis and a Phase II clinical trial for COVID-19. Another promising candidate, Namodenoson, is presently undergoing a Phase III trial for hepatocellular carcinoma and a Phase IIb trial for non-alcoholic steatohepatitis. Furthermore, CF602 is in its pre-clinical phase, with potential application for erectile dysfunction. Beyond drug development, Can-Fite also creates a commercial predictive biomarker blood test kit specifically for A3AR. The company maintains strategic partnerships, including a licensing and collaboration agreement with CMS Medical for the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. A separate collaborative venture with Univo Pharmaceuticals focuses on identifying and jointly developing specific cannabis component formulations intended for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Founded in 1994 as Can-Fite Technologies Ltd., the company rebranded to Can-Fite BioPharma Ltd. in January 2001, and operates from its headquarters in Petah Tikva, Israel.